BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34923044)

  • 1. Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3.
    Ma R; Liu Y; Che X; Li C; Wen T; Hou K; Qu X
    Cancer Lett; 2022 Feb; 527():127-139. PubMed ID: 34923044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
    Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF
    Feng D; Qin B; Pal K; Sun L; Dutta S; Dong H; Liu X; Mukhopadhyay D; Huang S; Sinicrope FA
    Oncogene; 2019 Oct; 38(41):6752-6766. PubMed ID: 31406255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
    Roshani Asl E; Rasmi Y; Baradaran B
    J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
    Kim JH; Park HE; Cho NY; Lee HS; Kang GH
    Br J Cancer; 2016 Aug; 115(4):490-6. PubMed ID: 27404452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
    Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
    Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer.
    Wang C; Weng M; Xia S; Zhang M; Chen C; Tang J; Huang D; Yu H; Sun W; Zhang H; Lai M
    Cancer Sci; 2021 Jan; 112(1):178-193. PubMed ID: 33058325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
    Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
    J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of tumor intrinsic PD-L1 confers resistance to drug-induced apoptosis in human colon cancer.
    Feng D; Chen Z; He X; Huang S; Zhang Z
    Neoplasma; 2021 Jan; 68(1):144-153. PubMed ID: 33030957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation.
    Ni W; Mo H; Liu Y; Xu Y; Qin C; Zhou Y; Li Y; Li Y; Zhou A; Yao S; Zhou R; Huo J; Che L; Li J
    Mol Ther; 2021 Oct; 29(10):2995-3010. PubMed ID: 33992804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3-mediated programmed death-ligand 1 expression in colorectal cancer.
    Min HY; Cho J; Sim JY; Boo HJ; Lee JS; Lee SB; Lee YJ; Kim SJ; Kim KP; Park IJ; Hong SM; Zhang XL; Zhang ZG; Park RW; Lee HY
    Clin Transl Med; 2022 Jul; 12(7):e986. PubMed ID: 35858011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
    Zhang H; Xia Y; Wang F; Luo M; Yang K; Liang S; An S; Wu S; Yang C; Chen D; Xu M; Cai M; To KKW; Fu L
    Adv Sci (Weinh); 2021 May; 8(10):2003404. PubMed ID: 34026438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.
    Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
    Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
    Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
    Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
    Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy.
    Wang HB; Yao H; Li CS; Liang LX; Zhang Y; Chen YX; Fang JY; Xu J
    J Dig Dis; 2017 Oct; 18(10):574-581. PubMed ID: 28851046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.
    Liao TT; Lin CC; Jiang JK; Yang SH; Teng HW; Yang MH
    Theranostics; 2020; 10(14):6095-6112. PubMed ID: 32483441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.